Skip to main content


Latest news from Alpine BioVentures & our portfolio companies

Portfolio Companies

Angion Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Alpine Immune Sciences announces $60 million private placement led by Omega Funds with participation from Avidity Partners, EcoR1 Capital, LLC, Invus Public Equities, LP, and Samsara BioCapital, among others

Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101

Angion Initiates Dosing in Phase 1 Trial of ANG-3070, a Dual Kinase Inhibitor for the Treatment of Fibrotic Diseases

Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Frazier Healthcare and Alpine BioVentures Join in $20M Series A Round for Mavupharma

Alpine Immune Sciences Completes Merger with Nivalis Therapeutics – Now Trading under ALPN on NASDAQ

Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

Alpine Immune Sciences Announces $48M Series A Financing

Why ex-Dendreon CEO’s New Startup Could Succeed

Former Dendreon CEO Launches Stealth Next-gen Immunotherapy Startup in Seattle

Seattle Biotech Oncothyreon Pays $27 million for Alpine Biosciences

A “Revolution”: Oncothyreon CEO on Alpine Biosciences Acquisition

Oncothyreon Announces Acquisition of Alpine Biosciences

UNM’s Protocell Technology Attracts Successful Entrepreneur, Investor, and Pioneer in Emerging Cancer Therapies

Protocell Cancer Therapy Gains Potent Backer